Journey Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for JOURNEY, and what generic alternatives to JOURNEY drugs are available?
JOURNEY has eight approved drugs.
There are twenty-eight US patents protecting JOURNEY drugs.
There are seventy-six patent family members on JOURNEY drugs in seventeen countries and fifteen supplementary protection certificates in nine countries.
Summary for Journey
| International Patents: | 76 |
| US Patents: | 28 |
| Tradenames: | 6 |
| Ingredients: | 4 |
| NDAs: | 8 |
| Patent Litigation for Journey: | See patent lawsuits for Journey |
Drugs and US Patents for Journey
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Journey | XIMINO | minocycline hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 201922-005 | Jul 11, 2012 | RX | No | No | 7,544,373 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Journey | XIMINO | minocycline hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 201922-003 | Jul 11, 2012 | RX | No | No | 7,541,347 | See Plans and Pricing | See Plans and Pricing | ||||
| Journey | QBREXZA | glycopyrronium tosylate | CLOTH;TOPICAL | 210361-001 | Jun 28, 2018 | RX | Yes | Yes | 10,543,192 | See Plans and Pricing | Y | See Plans and Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Journey
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Journey | XIMINO | minocycline hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 201922-001 | Jul 11, 2012 | 5,908,838 | See Plans and Pricing |
| Journey | QBREXZA | glycopyrronium tosylate | CLOTH;TOPICAL | 210361-001 | Jun 28, 2018 | 6,433,003 | See Plans and Pricing |
| Journey | XIMINO | minocycline hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 201922-003 | Jul 11, 2012 | 5,908,838 | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Journey Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Mexico | 2020002544 | See Plans and Pricing |
| Mexico | 2020012139 | See Plans and Pricing |
| Australia | 2015224534 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Journey Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1267866 | SPC/GB13/020 | United Kingdom | See Plans and Pricing | PRODUCT NAME: GLYCOPYRRONIUM OR A SALT THEREOF; REGISTERED: UK EU/1/12/788/001 20120928; UK EU/1/12/788/002 20120928; UK EU/1/12/788/003 20120928; UK EU/1/12/788/004 20120928; UK EU/1/12/788/005 20120928; UK EU/1/12/788/006 20120928 |
| 1267866 | 16/2013 | Austria | See Plans and Pricing | PRODUCT NAME: GLYCOPYRRONIUM, GLYCOPYRRONIUMSALZ; REGISTRATION NO/DATE: EU/1/12/788/001-006 20120928 |
| 1267866 | 2013C/023 | Belgium | See Plans and Pricing | PRODUCT NAME: GLYCOPYRRONIUM OU UN DE SES SELS; AUTHORISATION NUMBER AND DATE: EU/1/12/788/001 20121002 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
